Pegah Ebrahimi
Co-Founder and Managing Partner @ FPV Ventures
San Francisco Bay Area, United States
Pegah Ebrahimi is a Series A investor at FPV Ventures in San Francisco Bay Area focused on Artificial Intelligence and Software. Pegah Ebrahimi - Co-Founder and Managing Partner @ FPV Ventures
- Total investments:
- 19
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries Pegah Ebrahimi invests in
Stages Pegah Ebrahimi invests in
Countries Pegah Ebrahimi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Artificial Intelligence 6 (32%)
- Software 4 (21%)
- Information Technology 4 (21%)
- Machine Learning 3 (16%)
- Health Care 2 (11%)
Stage
- Series A 6 (32%)
- Series B 6 (32%)
- Seed 3 (16%)
- Series C 1 (5%)
- Series D 1 (5%)
Country
- United States 8 (42%)
- Spain 1 (5%)
- Finland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cognichip is an AI-first deep tech company focused on transforming the semiconductor industry by revolutionizing how chips are designed. The company has developed Artificial Chip Intelligence (ACI®), the world’s first physics-informed AI foundation model specifically tailored for semiconductor design | $60M / Series A / Apr 01, 2026 | ||
| Co:Helm builds AI assistants that utilizes ChatGPT built with healthcare operations as the core focus. Co:Helm's interopability engine allows users to seamlessly integrate with any EHR or EMR system in less than a day. Co:Helm automates Prior Authorization for Utilization Management teams using AI resulting in a massive 90% time saving. | $40M / Series B / Feb 12, 2026 | ||
| Aily Labs engages in developing digital artificial intelligence products. | $80M / Series B / Nov 06, 2025 | ||
| Oath Surgical is creating the surgical care of the future, one that is value-based by design, tech-powered, and led by surgeons. The first vertically integrated system that combines tech-first surgical centers with AI software. | $24M / Series A / Oct 06, 2025 | ||
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | ||
| XOPS delivers autonomous IT, finally. We eliminate the need for human middleware—the manual coordination between systems that drains resources and morale—by deploying a legion of goal-oriented robots that actually do the work. Unlike traditional automation that creates workflows in siloes or merely orchestrates human tasks, or systems ofintelligence that gather data but don’t act on it, XOPS provides an active system of intelligence that delivers truly autonomous IT operations through: 1. Total Enterprise Visibility that transforms fragmented data across IT, HR, and Finance systems into unified clarity. Our platform creates a single source of truth, eliminating the silos and blind spots that plague enterprise operations. 2. Unprecedented Operational Intelligence to let organizations make sense of the mass amounts of valuable telemetry they generate every day. 3. Complete Lifecycle Context, powered by our living knowledge graph, maintains real-time relationships between every employee, device, software component, and infrastructure element. This enables our software robots to understand dependencies, predict impacts, and execute with full lifecycle context. 4. A Legion of Goal-oriented Robots that don't just automate workflows or orchestrate employees but perform actual work autonomously. From employee onboarding to software license optimization, from device provisioning to infrastructure management and beyond, our robots execute complete processes end-to-end, 24x7, based on an organization’s policies. The result is IT that runs itself, with the sophistication and precision the world’s biggest enterprises need to keep hundreds of thousands of workers productive. That means IT teams shift to strategic oversight while leadership reclaims resources for innovation and sets a new bar for operational excellence. | $40M / Seed / Aug 14, 2025 | ||
| Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $153M / Series B / Aug 03, 2025 | ||
| Aibidia is a FinTech company that provides AI-powered transfer pricing management solutions to multinational corporations. The company's connected, end-to-end platform provides organizations the ability to take full control of their business and implement considered tax strategies across the entire group. Its platform automates complexcalculations, risk assessments, and scenario modeling, helping companies optimize their tax strategies and ensure compliance. | $28M / Series B / Jun 04, 2025 | ||
| Cognichip is an AI-first deep tech company focused on transforming the semiconductor industry by revolutionizing how chips are designed. The company has developed Artificial Chip Intelligence (ACI®), the world’s first physics-informed AI foundation model specifically tailored for semiconductor design | $33M / Seed / May 15, 2025 | ||
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $130M / Series C / Nov 21, 2024 | ||
| See all 19 investments → | |||
Co-Investors
About FPV Ventures
FPV Ventures is a venture capital investment firm.
FPV Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Pegah Ebrahimi
Co-Founder and Managing Partner
|
|||
Wesley Chan
Co-Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Pegah Ebrahimi invest in?
Pegah Ebrahimi invests primarily in Artificial Intelligence, Software and Information Technology startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pegah Ebrahimi?
Public channels for Pegah Ebrahimi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Pegah Ebrahimi last invest?
The most recent investment recorded for Pegah Ebrahimi closed in Apr 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
